WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[RH031 trade name]*

(Levonorgestrel 1.5 mg Tablet)

[RH031 trade name], manufactured at Famy Care Ltd, Ahmedabad, India was included in the WHO list of prequalified products for emergency contraception for women on 21 October 2013.

[RH031 trade name] is indicated for emergency contraception. Detailed information on the use of this product is described in the Summary of Product Characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient (API) of [RH031 trade name] is levonorgestrel.

The efficacy and the safety profile of levonorgestrel are well established based on extensive clinical experience in emergency contraception.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of levonorgestrel for emergency contraception, the team of WHO assessors accepted [RH031 trade name] for inclusion in the list of prequalified medicinal products.

Summary of prequalification status for [RH031 trade name]:

, and the second		
Initial acceptance	Date	Outcome
Status on PQ list	21 October 2013	listed
Quality	10 October 2013	MR
Bioequivalence	10 October 2013	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	NA	MR
FPP	06 September 2012	MR
GCP/GLP (re-)inspection	18 October 2012	NA
API: active pharmaceutical	GMP: good manufacturing practice	
ingredient	[quality standard]	
FPP: finished pharmaceutical	MR: meets requirements	
product	MR*: desk review (based on recent	
GCP: good clinical practice	inspection reports)	
[quality standard]	NA: not applicable, not available	
GLP: good laboratory practice [quality standard]	PQ: prequalification	

The table represents the status of relevant completed activities only.

Requalification 31 March 2020

^{*} Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility.

_

[†] Formerly Famy Care Ltd then Jai Pharma Ltd.